Company intelligence / Profile preview

Toxys

Ownership: Private
Development stage: Commercial

Overview

Toxys provides innovative animal-free in vitro toxicology testing platforms—most notably the stem cell-based ToxTracker®, which identifies genotoxic hazards and elucidates mechanisms of action. Their ReproTracker® assesses developmental toxicity without animal use. These technologies support pharmaceutical, chemical, cosmetic and food industries in early-stage compound safety evaluation to reduce late-stage failures due to unforeseen toxicities. The company’s platforms are internationally recognized for high-quality results and scientific rigor.

Therapeutic areas: OtherOncologyWomen's Health
Modalities: In vitro assayStem cell-based reporter assayHigh-throughput screening technology
Industry: Drug Discovery Services

Partnerships

Janssen FarmaceuticaProcter & GambleMedicines for Malaria Venture

Beyond the preview

Go deeper on Toxys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toxys.

Explore the full profile